ArriVent BioPharma, Inc. (AVBP) Financial Statements

77 Followers

ArriVent BioPharma, Inc. Financial Overview

ArriVent BioPharma, Inc.'s market cap is currently $1.30B. The company's EPS TTM is $-0.84; its P/E ratio is -4.65; ArriVent BioPharma, Inc. is scheduled to report earnings on March 5, 2026, and the estimated EPS forecast is $-0.90. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Operating Income	$ -177.53M	$ -94.31M	$ -74.59M	$ -36.91M	$ -8.70M
EBITDA	$ -177.53M	$ -80.49M	$ -74.59M	$ 0.00	$ -51.61M
Net Income	$ -166.31M	$ -80.49M	$ -69.33M	$ -36.91M	$ -51.61M
Balance Sheet
Cash & Short-Term Investments	$ 312.82M	$ 218.86M	$ 150.39M	$ 163.37M	$ 37.28M
Total Assets	$ 333.17M	$ 274.94M	$ 163.10M	$ 182.83M	$ 43.04M
Total Debt	$ 14.00K	$ 176.00K	$ 317.00K	$ 139.00K	$ 0.00
Net Debt	$ -45.53M	$ -74.12M	$ -150.07M	$ -163.23M	$ -37.28M
Total Liabilities	$ 25.95M	$ 17.29M	$ 11.80M	$ 8.37M	$ 1.82M
Stockholders' Equity	$ 307.22M	$ 257.65M	$ 151.30M	$ 174.46M	$ 41.22M
Cash Flow
Free Cash Flow	$ -160.59M	$ -70.21M	$ -55.84M	$ -43.63M	$ -12.59M
Operating Cash Flow	$ -160.59M	$ -70.21M	$ -55.84M	$ -43.63M	$ -12.59M
Investing Cash Flow	$ -71.23M	$ -192.47M	$ 0.00	$ 0.00	$ -40.00M
Financing Cash Flow	$ 203.06M	$ 186.58M	$ 42.86M	$ 169.72M	$ 89.87M

Currency in USD

ArriVent BioPharma, Inc. Earnings and Revenue History

Income Statement >

ArriVent BioPharma, Inc. Debt to Assets

Balance Sheet >

ArriVent BioPharma, Inc. Cash Flow

Cash Flow >

ArriVent BioPharma, Inc. Forecast EPS vs Actual EPS

Earnings >